Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease
Open accessThe DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.
Abstract
Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to AD and that affects endosomes and induces the progressive failure of lysosomes, each of which are directly linked by distinct mechanisms to neurodegeneration. The origins of ELN dysfunction and β‐amyloidogenesis closely overlap, which reflects their common genetic basis, the established early involvement of endosomes and lysosomes in amyloid precursor protein (APP) processing and clearance, and the pathologic effect of certain APP metabolites on ELN functions. Genes that promote β‐amyloidogenesis in AD (APP, PSEN1/2, and APOE4) have primary effects on ELN function. The importance of primary ELN dysfunction to pathogenesis is underscored by the mutations in more than 35 ELN‐related genes that, thus far, are known to cause familial neurodegenerative diseases even though different pathogenic proteins may be involved. In this article, I discuss growing evidence that implicates AD gene–driven ELN disruptions as not only the antecedent pathobiology that underlies β‐amyloidogenesis but also as the essential partner with APP and its metabolites that drive the development of AD, including tauopathy, synaptic dysfunction, and neurodegeneration. The striking amelioration of diverse deficits in animal AD models by remediating ELN dysfunction further supports a need to integrate APP and ELN relationships, including the role of amyloid‐β, into a broader conceptual framework of how AD arises, progresses, and may be effectively therapeutically targeted.—Nixon, R. A. Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 31, 2729–2743 (2017). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In summary, oxidative and/or nitrosative damage to multiple proteins, including synaptic proteins is very likely to contribute to the memory problems and other cognitive deficits, reduced ATP availability in neurons, and decreased clearance of abnormal proteins34, creating a “perfect storm” (or sTORm perhaps!) of detrimental cognitive effects in AD9,34,35,41,42.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“In addition to mTOR activation, insulin resistance can also result in neuronal glucose deficiency, with consequent decreased glucose metabolism, impaired ATP production, and dysfunction and/or death7,42”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“Activated mTORC1 is intimately involved in regulation of protein synthesis, autophagy, mitochondrial function, lipogenesis, ketogenesis, and insulin signaling, and is crucially linked to glucose metabolism, where it becomes activated by growth factors, amino acids, and high cellular energy status41,42 (Fig 2).”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“These oxidatively modified, and likely dysfunctional, proteins include ones associated with altered glucose metabolism, mTOR signaling (including inhibited autophagy and increased insulin resistance), and the proteostasis network42,61,62,65,66.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
In the citing paper
“This significant mediator of neuronal death is present in the early stages of AD, and evidence of impaired autophagy is also found in aMCI brain and PCAD brains41–43.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [42]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
2 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedIntegrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 171
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“Of particular relevance to AD, lipoprotein receptors mediate glia-derived cholesterol transport within the CNS, which is essential to form and maintain synapses (108).”
BackgroundExtensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
Self-citationCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Research works printed but not linked: 1
- 10.1111/j.1365-2990.2010.01062.x · doi:10.1111/j.1365-2990.2010.01062.x · Paper page
Cited by
Items 201–300 of 407
Microglial Lyzl4 Facilitates β‐Amyloid Clearance in Alzheimer's Disease
Pan, J., Zhong, J., Geng, J., Oberhauser, J., Shi, S., & Wan, J. (2024) · Advanced Science · doi:10.1002/advs.202412184 · Cited by 12
Kapadia, A., Theil, S., Opitz, S., Villacampa, N., Beckert, H., Schoch, S., Heneka, M. T., Kumar, S., & Walter, J. (2023) · Autophagy · doi:10.1080/15548627.2023.2252300 · Cited by 13
“Once internalized into neurons via endocytosis, Aβ can be sorted to autophagy-related and endo-lysosomal compartments [8,25,40,41].”
BackgroundParadoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model
Verheijen, B. M., Stevens, J., Gentier, R. J. G., Hekke, C. D. V. ‘., van den Hove, D., Hermes, D. J. H. P., Steinbusch, H. W. M., Ruijter, J. M., Grimm, M. O. W., Haupenthal, V. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.011 · Cited by 14
Volonté, C., Hu, G., Shaw, C. A., Claudio, V. J., dos Santos, J. A., Vaz, S. H., Sebastião, A. M., Balcar, V. J., Mozley, P. D., Verde, F., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004136 · Cited by 14
Manap, A. S. A., Madhavan, P., Vijayabalan, S., Chia, A. Y. Y., & Fukui, K. (2020) · PeerJ · doi:10.7717/peerj.10003 · Cited by 12
Lauritzen, I., Bini, A., Bécot, A., Gay, A.-S., Badot, C., Pagnotta, S., Chami, M., & Checler, F. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70019 · Cited by 12
“…findings from the work of Bretou et al. would support the above-described studies made on AD and Down’s syndrome models reporting a link between autophagy-endolysosomal defects and APP-CTF accumulation (Hung & Livesey, 2018; Im et al., 2023; Kaur et al., 2017; Lauritzen et al., 2016; Nixon, 2017).”
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
Ohno, M. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111475 · Cited by 13
Computer-assisted evaluation of plant-derived β-secretase inhibitors in Alzheimer’s disease
Ullah, M. A., Johora, F. T., Sarkar, B., Araf, Y., Ahmed, N., Nahar, A. N., & Akter, T. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00150-3 · Cited by 15
“The active site of the enzyme β - secretase is located in the extracellular domain and contains two key aspartate residues: Asp332 and Asp28 [11, 12].”
BackgroundFunctional Deficits of 5×FAD Neural Stem Cells Are Ameliorated by Glutathione Peroxidase 4
Dar, N. J., Na, R., & Ran, Q. (2022) · Cells · doi:10.3390/cells11111770 · Cited by 12
“Altered functions of autophagy-lysosomal degradation pathway are well-documented in AD [53,54].”
BackgroundVicente, M. C., Almeida, M. C., Bícego, K., Carrettiero, D., & Gargaglioni, L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180397 · Cited by 9
Cheng, F., Fransson, L., & Mani, K. (2020) · Glycobiology · doi:10.1093/glycob/cwaa120 · Cited by 12
Morais, G. P., Neto, I. V. D. S., Marafon, B. B., Ropelle, E. R., Cintra, D. E., Pauli, J. R., & da Silva, A. S. R. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31005 · Cited by 14
“Aβ agglomeration may occur either extracellularly (Nixon, 2017; Zuroff et al., 2017) or intracellularly (Caccamo”
BackgroundYoon, L., Botham, R. C., Verhelle, A., Wu, Y., Cole, C. M., Tan, E. P., Massey, L. A., Sanz-Martinez, P., Chou, C., Xu, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.509997 · Cited by 15
Niu, F., Sharma, A., Wang, Z., Feng, L., Muresanu, D. F., Sahib, S., Tian, Z. R., Lafuente, J. V., Buzoianu, A. D., Nozari, A., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.06.004 · Cited by 11
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2024) · Molecules · doi:10.3390/molecules29245936 · Cited by 11
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer’s disease
Zhou, R. Z., Gaunitz, S., Kirsebom, B., Lundin, B., Hellström, M., Jejcic, A., Sköldunger, A., Wimo, A. B., Winblad, B. G., Fladby, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105598 · Cited by 11
“74,75 We note that low blood N-glycosylation was not associated with CSF amyloid or tau biomarkers and did not predict future reduction of CSF A β 42/40 in the DDI cohort.”
Cordoș, B. A., Tero-Vescan, A., HAMPSON, I. N., Oliver, A. W., & SLEVIN, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18060829 · Cited by 11
“Lysosomal dysfunction results in the aberrant accumulation of A β and hyper-phosphorylated tau aggregates within neurons and the extracellular space, significantly accelerating neuronal degeneration and cognitive decline [9].”
Hermey, G., & Klein, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.361544 · Cited by 10
“The lysosomal enzymes PPT1 (CLN1), TPP1 (CLN2), CTSD (CLN10) and cathepsin F (CTSF) (CLN13) are targeted directly from the Golgi to lysosomes where these hydrolases are activated (Butz et al., 2020).”
BackgroundInfluentialBergkvist, L., Du, Z., Elovsson, G., Appelqvist, H., Itzhaki, L. S., Kumita, J. R., Kågedal, K., & Brorsson, A. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12773 · Cited by 11
Rethinking lysosomes and lysosomal disease
Walkley, S. U. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136155 · Cited by 17
VPS35 Downregulation Alters Degradation Pathways in Neuronal Cells
Filippone, A., Li, J.-G., & Praticò, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210701 · Cited by 12
Williams, R. S. B., & Bate, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.031 · Cited by 10
“Observations that the normal intracellular trafficking and endosomal sorting is dysregulated in AD (Toh and Gleeson, 2016) support the theory that endosome/lysosome dysfunction leads to the amyloidgenic processing of APP in endosomal and lysosomal compartments (Nixon, 2017).”
Aging is associated with a mild acidification in neocortical human neurons in vitro
Bonnet, U., Bingmann, D., Speckmann, E., & Wiemann, M. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1904-2 · Cited by 10
Nourbakhsh, F., Read, M. I., Barreto, G. E., & Sahebkar, A. (2020) · IUBMB Life · doi:10.1002/iub.2369 · Cited by 10
“The main symptom of this disease is the loss of short term memory, which with increasing disease severity leads to a decrease in cognitive behavior of the affected person.(80,83) Histologically, APP-carboxy terminal fragments (APP-CTFs) are an important part for Aβ formation.”
BackgroundRab3A interacts with spastin to regulate neurite outgrowth in hippocampal neurons
Yang, Y., Yang, J., Liang, Y., Zhang, G., Cai, Z., Zhang, Y., Lin, H., & Tan, M. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.12.066 · Cited by 11
Reinders, N. R., van der Spek, S. J. F., Klaassen, R. V., Koymans, K. J., MacGillavry, H. D., Smit, A. B., & Kessels, H. W. H. G. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.0393-24.2024 · Cited by 9
“Dysfunction of the endolysosomal network, which includes endocytic and autophagic pathways, has been recognized as an early characteristic of AD (Peric and Annaert, 2015; Nixon, 2017).”
Chen, X., Zuo, X., Becker, A., & Mobley, W. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70046 · Cited by 11
Chauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12
Abedin, M. J., & Kastanenka, K. V. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251411561 · Cited by 11
“105 Moreover, astrocytes near plaques release in fl am-matory cytokines, reactive oxygen species (ROS), and glio-transmitters, amplifying neuronal damage and synaptic dysfunction, further contributing to disease pathology.”
Ohno, M. (2023) · Frontiers in Dementia · doi:10.3389/frdem.2023.1161875 · Cited by 10
“…to faster forgetting in preclinical AD, via welldefined endosomal enlargement that precedes Aβ accumulation and accompanies accelerated endocytosis (Nixon, 2017). β-CTFdependent (but Aβ-independent) overactivation of Rab5, a small GTPase associated with early endosome, has been shown to cause…”
BackgroundA Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration
Ubina, T., Magallanes, M., Srivastava, S., Warden, C., Yee, J., & Salvaterra, P. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01007 · Cited by 9
Gautier, M. K., Kelley, C. M., Lee, S. H., Mufson, E. J., & Ginsberg, S. D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.09.002 · Cited by 9
“This leads to an accumulation of APPL1 on the surface of early endosomes and a pathological over-activation of Rab5 (Nixon, 2017; Pensalfini et al., 2020).”
BackgroundAlcantara‐Gonzalez, D., Kennedy, M., Criscuolo, C., Botterill, J. J., & Scharfman, H. E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01747-1 · Cited by 10
Kim, G., Jung, I., Park, M., Park, K., Lee, S. H., & Kim, W. (2022) · Scientific Reports · doi:10.1038/s41598-022-21044-3 · Cited by 9
Laili, I. N., Nasir, M. H. M., Jufri, N. F., Ibrahim, F. W., & Hamid, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114501 · Cited by 9
Marshall, K. E., Mengham, K., Spink, M. C., Vania, L., Pollard, H. J., Darrow, M. C., Duke, E., Harkiolaki, M., & Serpell, L. C. (2024) · Structure · doi:10.1016/j.str.2024.02.010 · Cited by 10
Asiamah, E. A., Feng, B., Guo, R., Yaxing, X., Du, X., Liu, X., Zhang, J., Cui, H., & Ma, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230658 · Cited by 9
Ashkavand, Z., Ryan, K. C., Laboy, J. T., Patel, R., Geller, B., & Norman, K. R. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106961 · Cited by 9
“…dysfunction are associated with PSEN mutations as well as observed in AD patients (Cataldo et al., 2000; Hung and Livesey, 2018; Lie and Nixon, 2019; Nixon, 2017; Nixon and Rubinsztein, 2024; Nixon et al., 2005; Reddy et al., 2016; Ryan et al., 2024; Sarasija et al., 2018; Sarasija and…”
InfluentialLysosomal homeostasis at the crossroads of neurodegeneration
Tito, S. D., & Tooze, S. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199845 · Cited by 11
“A β peptides are generated by sequential cleavage of amyloid precursor protein (APP), a trans-membrane protein involved in neuronal growth and synaptic repair, by β - and γ -secretases (96, 97).”
Ankul Singh, S., Ansari, M. N., Elossaily, G. M., Vellapandian, C., & Prajapati, B. G. (2024) · ACS Omega · doi:10.1021/acsomega.3c06328 · Cited by 8
Assessing Rab5 Activation in Health and Disease
Pensalfini, A., Jiang, Y., Kim, S., & Nixon, R. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1346-7_20 · Cited by 7
Self-citationIntralysosomal Amyloidogenesis and Proximity Labeling by Cathepsin CPreprint
Elias, R. D., Allen, S., Demiralp, I. I., O'Neill, R. T., Schäfer, J.-H., Siems, H., Montabana, E. A., Ermel, U. H., Ash, C. T., Abdurrob, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.23.696283 · Cited by 9
Autophagy and nutrigenomics: a winning team against chronic disease and tumors
Chiarelli, R., Caradonna, F., & Naselli, F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1409142 · Cited by 8
Coleman, P. D., Delvaux, E., Kordower, J. H., Boehringer, A. V., & Huseby, C. J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14555 · Cited by 8
Fourrière, L., & Gleeson, P. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1550211 · Cited by 6
“…and perturbation of the endocytic pathway is strongly associated with Alzheimer’s disease before the deposition of aggregated amyloid-β [for review (Nixon, 2017; Small et al., 2017; Cataldo et al., 2000)] and changes in the expression of endocytic trafficking genes are associated with a risk of…”
Ayyubova, G., Bablu, F. E., Rahimli, N., Aghayeva, L., Springer, E. M., Alghenaim, F., & Suzuki, Y. J. (2026) · Antioxidants · doi:10.3390/antiox15010066 · Cited by 9
“Lysosomes are essential for the degradation of misfolded proteins, including A β , and their dysfunction contributes to A β accumulation and neuronal damage [95].”
Toxic mechanisms of amyloid oligomers and therapeutic strategies
Ivanova, M. I., Rosa, C. L., & Ramamoorthy, A. (2026) · Protein Science · doi:10.1002/pro.70519 · Cited by 6
“Specifically, soluble A β oligomers accumulate within early endosomes, where they dysregulate endosomal maturation and fusion with lysosomes (Nixon, 2017; Park et al., 2022; Perez et al., 2015; Poon et al., 2013; Zhang et al., 2022).”
Vigier, M., Uriot, M., Djelti, F., Claudepierre, T., Hajj, A. E., Yen, F. T., Oster, T., & Malaplate, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136816 · Cited by 6
“…µ M for 24 h or in the presence of DHA (Gibco) at 0.5 µ M for 48 h. Cells were either recovered for Western blot analysis in RIPA lysis buffer (Sigma Aldrich) supplemented with 40 µ g/mL cOmplete Protease Inhibitor Roche (Sigma Aldrich) or for immunostaining after fixation in 4% paraformaldehyde.”
MethodInfluentialHuo, D., & Younan Xia, A. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800525 · Cited by 6
A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome
Chen, X. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.313044 · Cited by 7
“The plaques and tangles have been studied extensively, while the dysfunction of early endosome has been found to be impacted long before appearance of amyloid deposits and neurofibrillary tangles with amyloid beta (Aβ) of varing length and phosphorylated tau as the main components, respectively (Nixon, 2017; Chen and…”
BackgroundLiposomal Drug Delivery for Neurological Disorders: Advances and Challenges
Javed, A., Mandal, P., Khan, I., Singh, A. P., Akhtar, J., Maheshwari, S., & Prajapati, B. G. (2024) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/0118715249319942240903134353 · Cited by 7
Weiner, S., Sauer, M., Montoliu‐Gaya, L., Benedet, A. L., Ashton, N. J., González‐Ortiz, F., Simrén, J., Rahmouni, N., Tissot, C., Therriault, J., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00841-0 · Cited by 10
“While the AT(N) framework provides a foundation for defining AD through its core pathologies, numerous other processes are affected in the disease, such as synaptic signalling, metabolism, lysosomal function, immune response, repair and regeneration [10–12].”
Abouward, R., Abdelhafid, A. M., Wilkins, O. G., Lee, S.-Y., Ibrahim, F., Skehel, M., Ting, A. Y., Birsa, N., Ule, J., & Schiavo, G. (2026) · Journal of Cell Science · doi:10.1242/jcs.264466 · Cited by 7
“…several key pathogenic proteins, including tau, α - synuclein and amyloid precursor protein, hijack pre-existing transport routes and organelle subtypes for propagation across neuronal circuits (Abeliovich and Gitler, 2016; Nixon, 2017; Evrard et al., 2018; Soares et al., 2021; Xie et al., 2022).”
Biomolecular Markers of Brain Aging
Li, M., An, H., Wang, W., & Wei, D. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1627-6_9 · Cited by 9
Jaye, S., Sandau, U. S., McFarland, T. J., Woltjer, R. L., & Saugstad, J. A. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1426180 · Cited by 5
“This in turn results in endolysosomal disruption (Nixon, 2017; Colacurcio et al., 2018; Szabo et al., 2022) and various neuropathological outcomes such as A β 1–42 over production (Koo and Squazzo, 1994; Wu and Yao, 2009; Burrinha et al., 2021) and clearance deficits (Narayan et al., 2020) as well…”
BackgroundGeorgieva, I., Tchekalarova, J. D., Nenchovska, Z., Kortenska, L., & Tzoneva, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910294 · Cited by 6
“For instance, APP matures in the endoplasmic reticulum and Golgi apparatus, after which it can be translocated to the cell surface or it can enter the lysosomal pathway and undergo proteolytic degradation [11].”
BackgroundLatina, V., Atlante, A., Malerba, F., Regina, F. L., Balzamino, B. O., Micera, A., Pignataro, A., Stigliano, E., Cavallaro, S., Calissano, P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119683 · Cited by 5
“It involves an initial step in which membrane-bound APP is internalized and converges with Betasecretase-1 enzyme (BACE1) into Ras-related protein 5 (Rab5)-positive early endosomes where β-cleavage occurs [56,57] followed by its subsequent γ-secretase-dependent maturation in late endosomes/trans-Golgi network to give…”
BackgroundOhno, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231451 · Cited by 5
Fyke, Z., Johansson, R., Scott, A. I., Wiley, D., Chelsky, D., Zak, J. D., Al-Nakouzi, N., Koster, K. P., & Yoshii, A. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108537 · Cited by 7
Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease
Marian, O. C., Tran, C., & Don, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00023-3 · Cited by 5
Cyclodextrins as promising therapeutics against cholesterol overload
Zákány, F., Kovács, T., Szente, L., & Varga, Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00028-6 · Cited by 7
Garcia, M. G., Paulus, A., Vázquez‐Reyes, S., Klementieva, O. L., Gouras, G. K., Bachiller, S., & Deierborg, T. (2023) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2023.100663 · Cited by 8
“Both APP and βCTF likely have their own roles to play under physiological and pathological conditions (Martinsson et al., 2019; Nixon, 2017).”
BackgroundPrimary cilia in the mature brain: emerging roles in Alzheimer's disease pathogenesis
Huang, A. S., Li, A. S. M., & Hor, C. H. H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1650884 · Cited by 6
“Beyond Aβ and tau pathology, AD progression involves disruptions in cellular homeostasis, notably affecting endosomal-lysosomal clearance (Nixon, 2017).”
Tau pathology differs by sex in Alzheimer's disease in Down syndrome
Chen, X., Zuo, X., & Mobley, W. C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70838 · Cited by 7
Mutation of TRPML1 Channel and Pathogenesis of Neurodegeneration in Haimeria
Gao, J., Li, H., Lv, H., & Cheng, X. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03874-y · Cited by 6
Hossain, M. K., & Chae, H. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105905 · Cited by 5
Linking endo-lysosomal pH, sterol, and trafficking to neurodegenerative disease
Prasad, H., & Rao, R. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf034 · Cited by 5
Milham, L. T., Morris, G. P., Konen, L. M., Rentsch, P., Avgan, N., & Vissel, B. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1338065 · Cited by 5
“The causes of AD are currently unclear, with many genetic and non-genetic risk factors potentially contributing to disease pathogenesis (Nixon, 2017; Gong et al., 2018; Morris et al., 2018).”
BackgroundPeng, K. Y., Liemisa, B., Pasato, J., D’Acunzo, P., Pawlik, M., Heguy, A., Penikalapati, S. C., Labuza, A., Pidikiti, H., Alldred, M. J., et al. (2024) · Traffic · doi:10.1111/tra.12937 · Cited by 6
Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases
Grahl, M. V. C., Hohl, K. S., Smaniotto, T. Â., & Carlini, C. R. (2025) · Molecules · doi:10.3390/molecules30030687 · Cited by 5
“…clearance through the endosomal–lysosomal complex and the β CTF-induced hyperactivation of Rab5 (a GTPase) cause an increase in endosomes and consequently endocytosis, resulting in changes in synaptic plasticity; contribute to the hyper-phosphorylation of Tau; and cause neurodegeneration [42].”
Cannavo, C., Tosh, J., Fisher, E., & Wiseman, F. K. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.004 · Cited by 6
Corraliza-Gómez, M. (2021) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/51889 · Cited by 6
Tsourmas, K. I., Butler, C. A., Kwang, N. E., Sloane, Z. R., Dykman, K. J. G., Maloof, G. O., Prekopa, C. A., Krattli, R. P., El-Khatib, S. M., Swarup, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.21.619538 · Cited by 4
Biomarker Validation in NPC1 : Foundations for Clinical Trials and Regulatory Alignment
Casazza, K., Cologna, S. M., Berry‐Kravis, E., Jarnes, J. R., & Porter, F. D. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70075 · Cited by 6
BACE1 at the crossroads of a vicious circle between Alzheimer’s disease and diabetes mellitus
Ohno, M. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1730524 · Cited by 5
“…dysfunction and enlargement are well characterized as an earliest AD pathological event in a multiplicity of mouse models and human AD-derived cells (Nixon, 2017; Bourgeois et al., 2018; Kwart et al., 2019; Pulina et al., 2020) and induce A β disposal failure inside neurons, eventually leading to…”
A Question of Origins: Non-neuronal Sources of Amyloid-β
Sasmita, A. O., & Depp, C. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-025-01572-4 · Cited by 5
“Hence, we provide a brief overview of the intracellular compartmentalization of Aβ with implications for its extracellular release, a topic reviewed by others [49–52].”
Tumor Cell Migration May Be an Inherent “Foraging” Behavior
Zhao, F., Niu, H., Zhang, L., Shen, D., & Wang, L. (2026) · Medicine Advances · doi:10.1002/med4.70050 · Cited by 3
Rimal, S., Li, W., Khaket, T. P., Li, Y., Tantray, I., Li, Y., Bhurtel, S., Grinberg, L. T., Spina, S., Cobos, I., et al. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.07 · Cited by 6
Hudgins, A. D., Zhou, S., Arey, R. N., Rosenfeld, M. G., Murphy, C. T., & Suh, Y. (2024) · Neuron · doi:10.1016/j.neuron.2024.04.009 · Cited by 5
Targeting RPSA to modulate endosomal trafficking and amyloidogenesis in genetic Alzheimer's disease
Limone, A., Napoli, C., Napolitano, F., Imbò, B., Minopoli, G., Bagnoli, S., Izzo, A., Paladino, S., Nacmias, B., Matteis, M. A. D., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167753 · Cited by 3
Gujjala, V. A., Klimek, I., Klimek, I., Tyshkovskiy, A., Oz, N., Castro, J. P., Gladyshev, V. N., Newton, J. C., & Kaya, A. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01190 · Cited by 7
“…plaques and intracellular tau tangles are common AD pathologies, recent findings point to more compelling causes: impaired endolysosomal activity (Nixon, 2017), and energy homeostasis disruption; both of which are associated with congenital conditions characterized by dementia-like pathology…”
Mosser, S., Gerber, H., & Fraering, P. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15143 · Cited by 3
“Indeed, several studies have previously reported the degradation of APP-CTFs in the autophagic/lysosomal pathway [for reviews, see (Nixon, 2017; Zare-Shahabadi, Masliah, Johnson, & Rezaei, 2015)].”
BackgroundA bioinformatic investigation of proteasome and autophagy expression in the central nervous system
Watanabe, Y., Takeda, H., Honda, N., & Hanajima, R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18188 · Cited by 4
“Additionally, lysosomal dysfunction reportedly enhanced neurofibrillary tangle accumulation and neurotoxicity [26].”
BackgroundDai, L., Wang, X., Li, M. C., Li, J., Liu, Y., Wu, N., Meng, X., Lu, J., Zhang, J., & Chen, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155801 · Cited by 3
Are you TORCing tau me? Amyloid‐β blocks the conversation between lysosomes and mitochondria
Polanco, J. C., & Götz, J. (2018) · The EMBO Journal · doi:10.15252/embj.2018100839 · Cited by 3
“Lysosomal dysfunction has been linked to AD pathogenesis through promotion of the accumulation of insoluble and toxic protein aggregates, such as A b and tau, in the brain (Nixon, 2017).”
Aivazidis, S., Jain, A., Anderson, C. C., Orlicky, D. J., Rauniyar, A. K., Fritz, K. S., Harris, P. S., Siegel, D. M., Maclean, K. N., & Roede, J. R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/436782 · Cited by 3
NHE6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque LoadPreprint
Pohlkamp, T., Xian, X., Wong, C. H. Y., Durakoglugil, M. S., Werthmann, G. C., Saido, T., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436385 · Cited by 4
Long term rescue of Alzheimer’s deficits in vivo by one-time gene-editing of App C-terminusPreprint
Aulston, B. D., Gimse, K., Bazick, H., Kramár, E. A., Pizzo, D. P., Shavarebi, F., Rust, T., Rosa, S. G., Parra‐Rivas, L. A., Sun, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.08.598099 · Cited by 8
Nixon, R. A., Lee, J., Stavrides, P. H., Darji, S., Goulbourne, C. N., Berg, M. J., Mohan, P. S., Yang, D., Roussos, P., Bleiwas, C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5306901/v1 · Cited by 3
Self-citationHippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease
Odfalk, K. F., Wickline, J. L., Smith, S., Dobrowolski, R., & Hopp, S. C. (2024) · Hippocampus · doi:10.1002/hipo.23586 · Cited by 2
“Defects in the endosomal-lysosomal network can impact numerous homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways (Nixon, 2017).”
BackgroundInfluentialBabu, A., Jayan, A. S., Sethumadhavan, A., Geetha, M., Raghavan, C. T., Gopala, S., Krishnan, S., & Urulangodi, M. (2024) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01234-8 · Cited by 2
Understanding the pathophysiology of alzheimer's disease: Insights for early diagnosis
Alharbi, S. S., Alharbi, S. S., Alanazi, A. F., & Alomran, R. W. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15185 · Cited by 2
Jiang, Y., Sachdeva, K., Goulbourne, C. N., Berg, M. J., Peddy, J., Stavrides, P. H., Pensalfini, A., Pawlik, M., Malampati, S., Whyte, L. S., et al. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.2331-24.2025 · Cited by 3
“Further information is provided in the text and in more detail in reviews (Nixon, 2017; Nixon and Rubinsztein, 2024). neuronal early endosome appears to be resilient in the younger brain, while this homeostatic ability is lost during aging (Nuriel et al., 2017; Mathews and Levy, 2019).”
InfluentialSelf-citationWu, J., Lu, X., Zhang, J., Shuaihan, W., Lu, Z., Han, Y., Yang, R., Su, Y., Tan, C., Huo, D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117193 · Cited by 3
Zhai, Y., Nevian, T., Finn, D. P., & Kwakowsky, A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00025-0 · Cited by 2
Badot, C., Bini, A., Duplan, E., Checler, F., & Lauritzen, I. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02928-7 · Cited by 2
“In some studies, C99 degradation was proposed to depend mainly on the UPS [40–42], whereas others have suggested a key role of the lysosomal‒ autophagic degradation pathway [8, 12, 43, 44].”
Khachaturian, A. S., & Khachaturian, Z. S. (2023) · Care weekly · doi:10.14283/vme.2023.2 · Cited by 5
Progress on Tripterygium wilfordii Hook f. as a treatment option for neurodegenerative diseases
Zhang, Z., Zuo, T., Chen, M., Zang, C., Wang, Y., Wang, Y.-D., & Ma, S. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100545 · Cited by 2
Highly prevalent geriatric medications and their effect on β-amyloid fibril formation
Zaman, Z., Islam, R., Koganti, B., Falki, V., Osentoski, T., Graham, S. F., & Sharoar, M. G. (2024) · BMC Neurology · doi:10.1186/s12883-024-03930-7 · Cited by 2
Sleat, D. E., Maita, I., Banach-Petrosky, W. A., Larrimore, K. E., Liu, T. T., Cruz, D. L., Baker, L., Maxfield, F. R., Samuels, B. A., & Lobel, P. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.012 · Cited by 2
Metadata
- Authors
- Nixon, R. A.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Corresponding author
- Nixon, Ralph A.
- ORCID
- Nixon, Ralph A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2017-06-14
- Volume
- 31
- Issue
- 7
- Pages
- 2729-2743
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC6137496
- OpenAlex
- W2728546490
- Cited by
- 400
- References
- 218
- Citations by year
- 2026: 39 · 2025: 55 · 2024: 44 · 2023: 36 · 2022: 50 · 2021: 55 · 2020: 55 · 2019: 34 · 2018: 25 · 2017: 7
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- The FASEB Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- National Institutes of Health
- National Institute on Aging
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Alzheimer's disease, amyloid precursor protein, lysosomal dysfunction, endosomes, APP processing, presenilin 1, presenilin 2, APOE ε4, tauopathy, synaptic dysfunction, neurodegeneration, familial neurodegenerative disease, animal models of Alzheimer's disease, therapeutic target
- MeSH terms
- Alzheimer Disease, Gene Expression Regulation, Humans, Lysosomes, Endosomes, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.